A Diagnostic and Therapeutic Agent for Epithelial Cancers

Health Sciences Technologies for Licensing

Download PDF

The Technology

Researchers at the University of Tennessee have discovered that the odontogenic ameloblastassociated protein (ODAM) can be detected in human epithelial cancers, including those of breast, lung, and gastric origin as well as primary melanoma. The inventors also discovered that ODAMreactive antibodies are present in the serum of patients suffering from these same cancers. The research group of Dan Kestler has generated antibodies that can be used not only as research reagents but also may be developed into diagnostic kits for clinical monitoring of patients with melanoma or breast cancer. An ELISA assay has been developed that has potential for detecting cancer-related proteins in the blood of patients with breast cancer.

Benefits

Patents

Back to Technologies for Licensing